KF VENTURES
We invest in founder-led, science-led biotechnology companies
with non-incremental strategies for improving human health.
KF Ventures was founded by science and tech entrepreneurs looking to support like-minded entrepreneurs with ambitious ideas. History tells us that the paradigm shifts don't start from investor put-togethers, corporate insiders, large war chests, or industry celebrity boards, but from scrappy founders. Life sciences companies are no exception.
​
​
​
KF VENTURES
FEATURED INVESTMENTS
Herophilus is a neurotherapeutics discovery company based on next-generation scaled complex in vitro models.
Acquired by Roche, Oct 2023
Onc.AI is a digital health company on a mission to radically improve oncology decision making.
Series A, Jan 2023
Tegmine combines mass spectrometry, machine learning, and biology to develop highly selective antibody drug targets for oncology.
DotLab is a women’s healthcare technology company developing a circulating micro RNA blood test to diagnose active endometriosis.
Series A, Aug 2023
Waypoint uses spatial biology and pooled screening to develop optimized cell therapies.
Series A, Dec 2025
Stealth co.
Mol Dyn meets LLMs.